Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography.
We analysed the expression of dopamine receptor subtypes in the subthalamic nucleus by means of reverse transcriptase-polymerase chain reaction. We also studied, using autoradiography, all pharmacologically characterized dopamine receptors in four subregions of the subthalamic nucleus. For comparison, dopamine receptor subtypes were also evaluated in brain regions where they are more abundant and well characterized. The radioligands used were: [3H]SCH-23390, [3H]emonapride and [3H]2-dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene for dopamine D1, D2 and D3 receptors, respectively; and [3H]YM-09151-2 in the presence of raclopride for dopamine D4 receptors. Finally, we also evaluated the effect of unilateral 6-hydroxydopamine injection into the medial forebrain bundle on dopamine receptor levels expressed in the ipsilateral subthalamic nucleus. The lesion was estimated by decrease in the binding of [3H]WIN-35428, a specific dopamine transporter label. D1, D2 and D3 receptor messenger RNAs and binding sites were present in the subthalamic nucleus, but no messenger RNA for D4 receptors was found, although specific binding sites for these receptors were observed. As compared to the intact side, the 6-hydroxydopamine lesion did not change D1 receptors, increased D2 receptors, and decreased D3 receptors and the dopamine transporter. The results suggest that postsynaptic D1, D2 or D3 receptors can mediate the effect of dopamine on subthalamic nucleus neuronal activity. D4 receptors would mediate exclusively presynaptic effects. These results reinforce the idea that dopamine receptors in the subthalamic nucleus may play an important role in the physiology of the basal ganglia and in the pathophysiology of Parkinson's disease.
Flores
G
G
Instituto de Fisiología, Universidad Autónoma de Puebla, México.
Liang
J J
JJ
Sierra
A
A
Martínez-Fong
D
D
Quirion
R
R
Aceves
J
J
Srivastava
L K
LK
D000818:Animals; D001345:Autoradiography / Q000379:methods; D001549:Benzamides / Q000493:pharmacokinetics; D001552:Benzazepines / Q000493:pharmacokinetics; D018492:Dopamine Antagonists / Q000493:pharmacokinetics*; D008297:Male; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D011954:Receptors, Dopamine / Q000235:genetics* / Q000378:metabolism*; D017447:Receptors, Dopamine D1 / Q000235:genetics / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism; D050637:Receptors, Dopamine D3; D050638:Receptors, Dopamine D4; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013764:Tetrahydronaphthalenes / Q000493:pharmacokinetics; D013787:Thalamic Nuclei / Q000378:metabolism*; D014316:Tritium
D001549:Benzamides; D001552:Benzazepines; D018492:Dopamine Antagonists; C493595:Drd3 protein, rat; C493601:Drd4 protein, rat; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes; D014316:Tritium; D050638:Receptors, Dopamine D4; C030265:nemonapride; C031349:7-hydroxy-2-N,N-dipropylaminotetralin